Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Pharmaceuticals

Delayed Japan Exchange 08:01:45 2024-04-17 pm EDT 5-day change 1st Jan Change
391 JPY +2.89% Intraday chart for Sumitomo Pharma Co., Ltd. -3.22% -16.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise MT
Roivant's anti-inflammatory drug succeeds in mid-stage study RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical MT
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from S&P Japan 500 CI
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka CI
US Inflation Report Lifts Asian Stock Markets MT
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses MT
Japan's Nikkei slips after Fed chair signals delay in rate cut RE
Transcript : Sumitomo Pharma Co., Ltd., Q3 2024 Earnings Call, Jan 31, 2024
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Fed, China Property Outlooks Roil Asian Stock Markets MT
Japan's Nikkei rounds off 2023 with biggest yearly gain in a decade RE
Interest Rates, China Housing Measures Lift Asian Stock Markets MT
China Real Estate, FX Roil Asian Stock Markets MT
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for  Commercialisation of RYEQO® CI
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis CI
Japanese Shares End Higher on Tuesday After BOJ Kept Rate Unchanged; Shares of Nippon Electric Glass Jump Over 10% MT
Sumitomo Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024 CI
Flat China Price Report Dulls Asian Stock Markets MT
Japan stocks retreat from 33-year peak ahead of Fed policy decision RE
Japan stocks retreat from 33-year peak ahead of Fed policy decision RE
Japanese Shares Extend Gains on Week's Close on Strong Chinese Data; Tokyo Gas Rallies 4.62% MT
Chart Sumitomo Pharma Co., Ltd.
More charts
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.1%): veterinary drugs, food additives, industrial chemical products, etc. Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
380 JPY
Average target price
333.8 JPY
Spread / Average Target
-12.17%
Consensus
  1. Stock Market
  2. Equities
  3. 4506 Stock
  4. News Sumitomo Pharma Co., Ltd.
  5. Sumitomo Dainippon's H1 Attributable Profit Falls 2%; Shares Tank 16%